{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:45Z","timestamp":1793664825726,"version":"4.5.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to compare the efficacy and safety (infection events) between rituximab (RTX), tacrolimus (TAC), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) as induction therapies in lupus nephritis (LN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Electronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched from inception up to December 9, 2021. Bayesian network meta-analysis was used to combine the direct and indirect evidence of different drugs for LN patients. The pooled relative effects were shown using odds ratios (ORs) and 95% credible intervals\u00a0(CrIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nineteen studies (1,566 patients) met the inclusion criteria and were selected in the present study. The network meta-analysis reported that no statistically significant differences were found in partial remission (PR) and infection among the four drugs. RTX showed a significantly higher complete remission (CR) than MMF (OR = 2.60, 95% CrI = 1.00\u20137.10) and seemed to be more effective than CYC (OR = 4.20, 95% CrI = 1.70\u201314.00). MMF had a better CR than CYC (OR = 1.60, 95% CrI = 1.00\u20133.20). TAC presented a better overall response than CYC (OR = 3.70, 95% CrI = 1.20\u201312.00). Regarding CR and overall response, the maximum surface under the cumulative ranking curve (SUCRA) values were 96.94% for RTX and 80.15% for TAC. The maximum SUCRA value of infection reaction was 74.98% for RTX and the minimum value was 30.17% for TAC, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>RTX and TAC were the most effective drugs for induction remission in LN. Among the four drugs, TAC had the lowest probability of infection, and RTX showed the highest probability of experiencing an infection. This meta-analysis could not conclude about other adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.859380","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:56:29Z","timestamp":1649048189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Kang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616","article-title":"Update on Lupus Nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000511268","article-title":"Update on Lupus Nephritis: Looking for a New Vision","volume":"145","author":"Morales","year":"2021","journal-title":"Nephron"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on Lupus Nephritis: Core Curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.78gr.11004","article-title":"New and Future Therapies for Lupus Nephritis","volume":"79","author":"Appel","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus Use in Lupus Nephritis: A Systematic Review and Meta-Analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B6","article-title":"A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy","volume":"32","author":"Gul","year":"2020","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312448105","article-title":"Tacrolimus Versus Cyclophosphamide as Treatment for Diffuse Proliferative or Membranous Lupus Nephritis: A Non-Randomized Prospective Cohort Study","volume":"21","author":"Wang","year":"2012","journal-title":"Lupus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-Term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu1028oa","article-title":"Cyclophosphamide: New Approaches for Systemic Lupus Erythematosus","volume":"13","author":"Petri","year":"2004","journal-title":"Lupus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-3166-9","article-title":"Analysis of the Effectiveness and Safety of Rituximab in Patients With Refractory Lupus Nephritis: A Chart Review","volume":"35","author":"Contis","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430","article-title":"B Cell Depletion as a Novel Treatment for Systemic Lupus Erythematosus: A Phase I\/II Dose-Escalation Trial of Rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200405000-00003","article-title":"B Cells as Therapeutic Targets for Rheumatic Diseases","volume":"16","author":"Looney","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.10541","article-title":"An Open Study of B Lymphocyte Depletion in Systemic Lupus Erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3583-x","article-title":"Efficacy and Safety of Rituximab in Comparison With Common Induction Therapies in Pediatric Active Lupus Nephritis","volume":"32","author":"Basu","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs. Mycophenolate and vs. Cyclophosphamide Pulses for Induction Therapy of Active Lupus Nephritis: A Clinical Observational Study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875","article-title":"Combination of Direct and Indirect Evidence in Mixed Treatment Comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B19","article-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analyses","volume-title":"Symposium on Systematic Reviews: Beyond the Basics: 2014","author":"Wells","year":"2014"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211432219","article-title":"A Practical Introduction to Multivariate Meta-Analysis","volume":"22","author":"Mavridis","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical Methods and Numerical Summaries for Presenting Results From Multiple-Treatment Meta-Analysis: An Overview and Tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028","article-title":"Et Al: Mycophenolate Mofetil Versus Cyclophosphamide for Induction Treatment of Lupus Nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 Month Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis With Nephrotic Syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrol (Carlton)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/RHU.0000000000000760","article-title":"Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-To-Head Comparative Study","volume":"25","author":"Goswami","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312458466","article-title":"Efficacy of Mycophenolate Mofetil in Adolescent Patients With Lupus Nephritis: Evidence From a Two-Phase, Prospective Randomized Trial","volume":"21","author":"Sundel","year":"2012","journal-title":"Lupus"},{"key":"B27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/s10165-012-0634-9","article-title":"Mycophenolate Mofetil Versus Intravenous Cyclophosphamide for Induction Treatment of Proliferative Lupus Nephritis in a Japanese Population: A Retrospective Study","volume":"23","author":"Onishi","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307081340","article-title":"Induction Therapies for Class IV Lupus Nephritis With Non-Inflammatory Necrotizing Vasculopathy: Mycophenolate Mofetil or Intravenous Cyclophosphamide","volume":"16","author":"Wang","year":"2007","journal-title":"Lupus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2007.07.006","article-title":"Induction Therapy for Pediatric Focal Proliferative Lupus Nephritis: Cyclophosphamide Versus Mycophenolate Mofetil","volume":"22","author":"Lau","year":"2008","journal-title":"J Pediatr Health Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-010-0270-7","article-title":"Is Mycophenolate Mofetil Superior to Pulse Intravenous Cyclophosphamide for Induction Therapy of Proliferative Lupus Nephritis in Egyptian Patients","volume":"14","author":"El-Shafey","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12882-018-0973-7","article-title":"Low Dose Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Therapy of Lupus Nephritis in Nepalese Population: A Randomized Control Trial","volume":"19","author":"Sedhain","year":"2018","journal-title":"BMC Nephrol"},{"key":"B32","article-title":"Mizoribine Versus Mycophenolate Mofetil or Intravenous Cyclophosphamide for Induction Treatment of Active Lupus Nephritis","volume":"127","author":"Feng","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.4103\/1319-2442.215147","article-title":"Mycophenolate mofetil or Cyclophosphamide in Indian Patients With Lupus Nephritis: Which Is Better? A Single-Center Experience","volume":"28","author":"Mendonca","year":"2017","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13274","article-title":"Outcome and Predictors of Renal Survival in Patients With Lupus Nephritis: Comparison Between Cyclophosphamide and Mycophenolate Mofetil","volume":"21","author":"Joo","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized Controlled Trial of Pulse Intravenous Cyclophosphamide Versus Mycophenolate Mofetil in the Induction Therapy of Proliferative Lupus Nephritis","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus Versus Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Randomised Controlled Trial and Long-Term Follow-Up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2994-2","article-title":"Network Meta-Analysis for Comparing Treatment Effects of Multiple Interventions: An Introduction","volume":"34","author":"Catal\u00e1-L\u00f3pez","year":"2014","journal-title":"Rheumatol Int"},{"key":"B38","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous Comparison of Multiple Treatments: Combining Direct and Indirect Evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"Bmj"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315595131","article-title":"Relative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide as Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Lee","year":"2015","journal-title":"Lupus"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.227.281","article-title":"A Meta-Analysis of Randomized Controlled Trials Comparing Tacrolimus With Intravenous Cyclophosphamide in the Induction Treatment for Lupus Nephritis","volume":"227","author":"Deng","year":"2012","journal-title":"Tohoku J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0961203320928412","article-title":"Rituximab Use as Induction Therapy for Lupus Nephritis: A Systematic Review","volume":"29","author":"Stolyar","year":"2020","journal-title":"Lupus"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v20i2.41","article-title":"Efficacy and Safety of Rituximab for Systemic Lupus Erythematosus Treatment: A Meta-Analysis","volume":"20","author":"Wu","year":"2020","journal-title":"Afr Health Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II\/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical Review: Serious Adverse Events Associated With the Use of Rituximab - A Critical Care Perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in Systemic Lupus Erythematosus: A Systematic Review of Off-Label Use in 188 Cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5414\/CNP75233","article-title":"Geographical Variation in the Response of Lupus Nephritis to Mycophenolate Mofetil Induction Therapy","volume":"75","author":"Mohan","year":"2011","journal-title":"Clin Nephrol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50039","article-title":"Beneficial Effects of Weight Loss in Overweight Patients With Chronic Proteinuric Nephropathies","volume":"41","author":"Morales","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3967\/bes2016.095","article-title":"Effects of Endurance and Endurance-Strength Exercise on Renal Function in Abdominally Obese Women With Renal Hyperfiltration: A Prospective Randomized Trial","volume":"29","author":"Szuli\u0144ska","year":"2016","journal-title":"BioMed Environ Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.859380\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:56:37Z","timestamp":1649048197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.859380\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.859380"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.859380","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"article-number":"859380"}}